WuXi Biologics Sweeps 2024 CDMO Leadership Awards Across the Board
WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), trading as WuXi Bio (2269.HK), proudly announces its sweeping victory at the 2024 CDMO Leadership Awards. The company…
FDA Approves Astellas’ Supplemental New Drug Application for IZERVAY™ to Treat Geographic Atrophy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, referred to as “Astellas”) has received notification from the U.S. Food and Drug Administration (FDA) regarding the acceptance of the…
Eisai Seeks FDA Approval for IV Maintenance Dosing of LEQEMBI® in Early Alzheimer’s Treatment
Eisai Co., Ltd. (based in Tokyo, CEO: Haruo Naito) and Biogen Inc. (headquartered in Cambridge, Massachusetts, CEO: Christopher A. Viehbacher) have jointly announced the submission of a Supplemental Biologics License…
Avian Influenza Epidemics in 2023
The recent occurrences of avian influenza outbreaks, observed last year, underscore the sobering reality of zoonotic influenza. These events emphasize that individuals of all ages are susceptible, regardless of comorbidities,…
Swine Influenza Outbreaks in 2023
Last year witnessed several outbreaks that underscore the reality of zoonotic influenza, revealing vulnerabilities across all age groups and highlighting the risks for individuals both with and without comorbidities. These…
Progress in Clinical Development of Efgartigimod for Primary Sjogren’s Disease by Argenx
A global immunology company dedicated to enhancing the lives of individuals grappling with severe autoimmune conditions has unveiled its intention to propel the development of efgartigimod into Phase 3 for…
CVS Health® Allocates Over $3 Million to Organizations Enhancing Health Outcomes in Phoenix
The CVS Health® (NYSE: CVS) today announced more than $3 million in new grants to support organizations in Phoenix working to increase equitable access to health care, address social determinants of…
Bristol Myers Squibb Confirms Success of KRAZATI Trial in KRAS G12C-Mutated Lung Cancer
Bristol Myers Squibb (NYSE: BMY) has announced the successful results of the pivotal Phase 3 KRYSTAL-12 study, which evaluated KRAZATI® (adagrasib) as a monotherapy for patients with previously treated locally…
Bristol Myers Squibb Updates Phase 3 YELLOWSTONE Trial Progress: Oral Zeposia (Ozanimod) Evaluation in Moderate to Severe Active Crohn’s Disease Patients
Bristol Myers Squibb (NYSE: BMY) provided an update today following the preliminary analysis of findings from the first of two induction studies within the Phase 3 YELLOWSTONE clinical trial program,…
Bristol Myers Squibb Broadens Health Equity Grant Programs for Enhanced Health Results
Bristol Myers Squibb (NYSE: BMY) has introduced a $1.8 million initiative aimed at promoting health equity by tackling social determinants of health (SDoH) in four countries with underserved patient populations:…
Bristol Myers Squibb Presents New Cardiovascular Findings at 2024 ACC Conference, Strengthening Evidence Base
Bristol Myers Squibb (NYSE: BMY) announced today the unveiling of data at the American College of Cardiology (ACC) Annual Scientific Session & Expo, scheduled for April 6-8, 2024, in Atlanta,…
FDA Approves Roche’s Groundbreaking Molecular Test for Malaria Screening in Blood Donors
Roche, a leading healthcare company (SIX: RO, ROG; OTCQX: RHHBY), has announced today the approval by the U.S. Food and Drug Administration (FDA) for its cobas® Malaria test, designed for…